Dendritic cells based immunotherapy of patient with chondrosarcoma--case report.

Abstract

Abstract:We present a case report of patient with intracranial chondrosarcoma and attempt to use vaccination of dendritic cells as the salvage therapy. To our knowledge, this is the first case report of DCs vaccination in the head and neck chondrosarcoma. Immunotherapy with allogeneic DCs stimulated with tumor cell lysates in this case was demonstrated to be feasible, safe and well tolerated. Unfortunately we did not observe any clinical or immune response during vaccination. CD4+ and CD8+ regulatory cells could be responsible for ineffectiveness of immunotherapy.

Molecular oncogenesis of chondrosarcoma: impact for targeted treatment

“…Loss of p16 protein expression was found to correlate with histological grade of central chondrosarcomas [64]. In dedifferentiated chondrosarcoma, mesenchymal, clear cell chondrosarcoma and periosteal chondrosarcoma, p16 aberrations were found to be common (85,70,95 and 50% of cases, respectively) [14,17]. One study [62 & ] reported that the pRb pathway is affected in 96% of the high-grade central chondrosarcomas, either by a decrease in the amount of CDKN2A/p16 (48%), an increase in the amount of CDK4 (55%) or expression of cyclin D1 (62%).…”

“…Specific CD8 þ T cells against these antigens were able to specifically lyse chondrosarcoma cell lines in vitro [81,83]. One study [85] reported a patient with an intracranial chondrosarcoma who received allogeneic dendritic cell vaccination stimulated with tumour cell lysate, without any clinical or immune response during vaccination. No T-cell-mediated immunotherapeutic trial against chondrosarcoma-associated targets for chondrosarcoma patients has been published or is ongoing at the moment.…”

Cryoimmunology for malignant bone and soft-tissue tumors

“…CD4 + and CD8 + T regulatory cells could be responsible for the ineffectiveness of this particular immunotherapy [21].…”